IDEXX Slides 0.65% as 362nd-Ranked U.S. Stock Balances Global Growth with Domestic Challenges

On August 25, 2025, IDEXX Laboratories (IDXX) closed down 0.65% with a trading volume of $250 million, ranking 362nd in activity among U.S. equities. The stock’s recent performance reflects a mix of strong fundamentals and sector-specific challenges. Recent reports highlight robust international growth in companion animal diagnostic recurring revenues, driven by double-digit expansion in consumable sales for Catalyst and inVue Dx platforms. IDEXX also reported 92-basis-point gross margin expansion to 62.6% in Q2 2025, alongside a 541% year-over-year increase in operating profit to $373.1 million.

Cloud-based solutions are emerging as a key growth driver, with IDEXX’s ezyVet and Neo platforms achieving double-digit placement growth in Q2. The company raised its 2025 revenue guidance to $4.21–$4.28 billion, with full-year EPS projected at $12.40–$12.76, signaling 16–20% year-over-year growth. However, U.S. same-store clinical visits declined 2.5% in the same quarter, underscoring staffing challenges in veterinary clinics. While international momentum remains strong, risks from geopolitical tensions and currency fluctuations could temper long-term gains.

The strategy of buying the top 500 stocks by daily trading volume and holding for one day from 2022 to 2025 returned 31.52% over 365 days, with a 0.98% average daily return. Performance varied significantly, peaking at 7.02% in June 2023 and hitting a low of -4.65% in September 2022, illustrating short-term volatility inherent in volume-driven strategies.